Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatrogon once weekly versus Genotropin once daily in growth hormone-naive children with short stature due to small for gestational age or idiopathic short stature
MOH_2025-12-17_015550Phase 3Not yet recruiting
- Sponsor
- Schneider Children's Medical Center of Israel
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Short stature in children born small for gestational age and Idiopathic Short Stature (ISS) comparing Somatrogon weekly with Genotropin daily (2 arms). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
somatrogonsomatropin
03
Conditions
Short stature in children born small for gestational ageIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on MOH_2025-12-17_015550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-17_015550.